Sunshine Biopharma Inc. Impairment of Intangible Assets, Finite-lived
Sunshine Biopharma Inc. (SBFM) reported Impairment of Intangible Assets, Finite-lived of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2026-08-13
- Sunshine Biopharma Inc. impairment of intangible assets, finite-lived for the quarter ending 2026-06-30 was $0.00.
- Sunshine Biopharma Inc. impairment of intangible assets, finite-lived for the quarter ending 2026-03-31 was $0.00.
- Sunshine Biopharma Inc. impairment of intangible assets, finite-lived for the quarter ending 2025-12-31 was -$131.79K.
- Sunshine Biopharma Inc. impairment of intangible assets, finite-lived for the quarter ending 2021-12-31 was $0.00.
- Sunshine Biopharma Inc. impairment of intangible assets, finite-lived for fiscal 2021 was $556.12K, a 0.00% change from fiscal 2020.
- Sunshine Biopharma Inc. impairment of intangible assets, finite-lived for fiscal 2020 was $556.12K.
- Sunshine Biopharma Inc. impairment of intangible assets, finite-lived for fiscal 2018 was $556.12K, a 0.00% change from fiscal 2017.
- Sunshine Biopharma Inc. impairment of intangible assets, finite-lived for fiscal 2017 was $556.12K.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | -$131.79K derived: sum of 3 quarters · filed 2026-08-13 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-13 | -$131.79K derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-12-31 | -$131.79K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-13 | -$1.75M 10-Q · filed 2026-08-13 | ||
| 2025-09-30 | -$1.62M 10-Q · filed 2025-11-13 | |||
| 2024-12-31 | $0.00 10-Q · filed 2025-11-13 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $0.00 derived: sum of 2 quarters · filed 2022-03-21 | $0.00 derived: sum of 3 quarters · filed 2022-03-21 | $556.12K 10-K · filed 2022-03-21 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 derived: sum of 2 quarters · filed 2021-11-09 | $556.12K 10-Q · filed 2021-11-09 | $556.12K derived: sum of 4 quarters · filed 2022-03-21 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $556.12K 10-Q · filed 2021-08-09 | $556.12K derived: sum of 3 quarters · filed 2022-03-21 | |
| 2021-03-31 | $556.12K 10-Q · filed 2021-05-11 | $556.12K derived: sum of 2 quarters · filed 2022-03-21 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $556.12K 10-K · filed 2022-03-21 | ||
| 2020-09-30 | $556.12K 10-Q · filed 2020-11-12 | |||
| 2019-12-31 | $556.12K 10-Q · filed 2020-11-12 | |||
| 2018-12-31 | $556.12K 10-K · filed 2019-04-12 | |||
| 2017-12-31 | $556.12K 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |